The US drug regulator has completed inspection of the facility of Granules India's US-based subsidiary on 25 June 2021 with two minor observations.
The United States Food and Drug Administration (USFDA) has completed the inspection of the facility of Granules Pharmaceuticals, Inc., a wholly owned foreign subsidiary of the company located in Chantilly, Virginia, USA on Friday, 25 June 2021 with two minor observations.
This is a pre-approval inspection for the products filed from this facility. Granules Pharmaceuticals, Inc. will respond to these observations within the stipulated time.
Granules India's consolidated net profit jumped 38.2% to Rs 127.57 crore on 33.2% surge in net sales to Rs 799.31 crore in Q4 FY21 over Q4 FY20.
Granules India is a growing pharmaceutical manufacturing company. The company produces finished dosages (FDs), pharmaceutical formulation intermediates (PFIs) and active pharmaceutical ingredients (APIs). The company's global presence extends to over 250 customers in 60 countries through offices in India, US, and UK.
Shares of Granules India rose 1% to Rs 317.10 on BSE. The stock traded in the range of Rs 312 to Rs 317.85 during the day.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU